Top Articles

Representatives from key organisations in neurology detailed their actions for a European advocacy in the brain space in a Studio Session held on the third day of EAN 2023.

This special session organised by the European Federation of Neurological Associations covered the up-to-date unmet needs and future challenges in rare neurological diseases from the perspective of patients’ associations.

The amount of data available in neurology, neuroscience, neurobiology and related disciplines is rising exponentially and challenging clinicians’ ability to analyse and use that data, a panel of experts showed in a Plenary Session on day three of EAN 2023.

EAN Website Editor Letizia Leocani talks to Prof. Mark Hallett, National Institutes of Health Distinguished Investigator Emeritus, who gave the C. Brown-Séquard Lecture at this year’s congress.

Four distinguished neurologists delivered the prestigious named lectures during the Presidential Symposium, held on the second day of EAN 2023.

Top neurologists gathered to discuss challenges for women in neurology in a dedicated session chaired by President Elect Elena Moro on the second day of EAN 2023.

EANpages Editor Benedetta Bodini talks to Prof. Josep Dalmau, Professor at the Catalan Institution for Research and Advanced Studies (ICREA)-IDIBAPS, University of Barcelona, who will give the Camillo Golgi Lecture at this year’s congress.

The European Academy of Neurology (EAN) is a young society ready for the future, according to its president Prof. Paul Boon, who delivered his welcome address in the Opening Session on the first day of EAN 2023

The popular Basal Ganglia Club reconvened again at EAN 2023 in Budapest, featuring both the MDS-ES C. David Marsden Award Lecture and the Dystonia Europe David Marsden Award Lecture.

Leading neurologists discussed how to promote brain health and overcome the global burden of brain disorders in a dedicated Studio Session on the first day of EAN 2023.

Symposium 3 at EAN 2023, on the glymphatic system, sleep and neurodegeneration, opened exciting new possibilities for future treatments, linking sleep quality and brain clearance to potentially modify a range of neurological diseases.

Co-Chair of the EAN Scientific Panel on Dementia and Cognitive Disorders answers three key questions about a groundbreaking Alzheimer study.

Watch a full recording of the European Brain Health Summit 2023, held on 9 May, featuring key international voices on precision neurology and the prevention of neurological diseases.

Our paper of the month is a phase 1b, randomised, multicentre, placebo-controlled trial, which aims to investigate the safety, pharmacokinetics, and effects of MAPTRx in patients with mild Alzheimer's.

Join our team of leading experts, policymakers and stakeholders on a journey through the European brain health landscape on May 9.